Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4739223

CCc1ccc([N+](=O)[O-])cc1.N

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.59
▸ MAPT P10636 4/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ ACHE P22303 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ IDO1 P14902 2/20 0.53
▸ CYP2C19 P33261 3/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPBWR1 P48145 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ CRHBP P24387 1/20 0.49
▸ CRHR2 Q13324 1/20 0.49
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128402 0.98 LOXL2 (0.61) LOXL2MAPTMEN1KMT2ATSHR
Bromide SCHEMBL2771283 0.95 LOXL2 (0.59) LOXL2MAPTMEN1KMT2ATSHR
SCHEMBL14071658 0.91 LOXL2 (0.55) LOXL2MAPTMEN1KMT2ATSHR
SCHEMBL10915611 0.91 POLB (0.63) LOXL2MAPTMEN1KMT2ATSHR
Bicarbonate SCHEMBL31202990 0.90 MAPT (0.55) LOXL2MAPTMEN1KMT2ATSHR
SCHEMBL11089722 0.86 LOXL2 (0.50) LOXL2MAPTMEN1KMT2ATSHR
SCHEMBL11347524 0.86 L3MBTL1 (0.61) LOXL2MAPTMEN1KMT2AHSD17B10
SCHEMBL4416673 0.86 HSPB1 (0.59) LOXL2MAPTMEN1KMT2ATSHR
SCHEMBL8957256 0.85 MAPT (0.51) LOXL2MAPTMEN1KMT2ATSHR
Ammonia Solution, Strong SCHEMBL18045579 0.83 TSHR (0.62) LOXL2MAPTTSHRACHEHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0498590-B1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes LILLY CO ELI (US) 1997-04-09 — — EP claimed
EP-0498590-A1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes ELI LILLY AND COMPANY (US) 1992-08-12 — — EP claimed
WO-2008086462-A2 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2008-07-17 — — WO disclosed
US-7196084-B2 Cdc25 phosphatase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-27 — — US disclosed
US-20060235027-A1 Inhibitors of cdc25 phosphatases SCRAS 2006-10-19 — — US disclosed
US-20060154933-A1 Inhibitors of Cdc25 phosphatases SCRAS 2006-07-13 — — US disclosed
US-20040034103-A1 Cdc25 photophatase inhibitors IPSEN PHARMA S.A.S. (FR) 2004-02-19 — — US disclosed
EP-0712837-B1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes LILLY CO ELI (US) 2000-10-25 — — EP disclosed
EP-0683155-B1 Tetrahydrobenz cd indoles with serotonin regulatory activity LILLY CO ELI (US) 1998-07-01 — — EP disclosed
US-5637624-A ANTISEROTONIN AGENT ELI LILLY AND COMPANY (US) 1997-06-10 — — US disclosed
EP-0498590-B1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes LILLY CO ELI (US) 1997-04-09 — — EP disclosed
US-5340838-A Administering serotonin agonist to mammals ELI LILLY AND COMPANY (US) 1994-08-23 — — US disclosed
US-5286753-A Serotonin 1a receptor agonists ELI LILLY AND COMPANY (US) 1994-02-15 — — US disclosed
US-5258379-A ADMINISTERING IN AN EFFECTIVE DOSAGE TO MAMMALS ELI LILLY AND COMPANY (US) 1993-11-02 — — US disclosed
US-5158956-A Administering serotonin receptor agonist ELI LILLY AND COMPANY (US) 1992-10-27 — — US disclosed
EP-0498590-A1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes ELI LILLY AND COMPANY (US) 1992-08-12 — — EP disclosed
US-5096908-A 5-HT1A agonist ELI LILLY AND COMPANY (US) 1992-03-17 — — US disclosed
EP-0471515-A1 Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes ELI LILLY AND COMPANY (US) 1992-02-19 — — EP disclosed
EP-0455510-A2 Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion ELI LILLY AND COMPANY (US) 1991-11-06 — — EP disclosed
EP-0385658-A1 Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes ELI LILLY AND COMPANY (US) 1990-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034103-A1 Cdc25 photophatase inhibitors CDC25C, CDC25A, CDC25B LOXL2 4552/4885MAPT 4678/4885MEN1 3563/4885
US-20060154933-A1 Inhibitors of Cdc25 phosphatases CDC25A, CDC25C, CDC25B LOXL2 4122/4885MAPT 4147/4885MEN1 1858/4885
US-20060235027-A1 Inhibitors of cdc25 phosphatases CDC25A, CDC25C, CDC25B LOXL2 4122/4885MAPT 4147/4885MEN1 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.